Animal models of rheumatoid arthritis: How informative are they? by McNamee, Kay et al.
ANIMAL MODELS OF RHEUMATOID ARTHRITIS: HOW 
INFORMATIVE ARE THEY? 
 
 
Kay McNamee1, Richard Williams1 and Michael Seed2 
 
Eur J Pharmacol. 2015 Mar 27. pii: S0014-2999(15)00264-2. doi: 
10.1016/j.ejphar.2015.03.047. 
 
 
1Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Oxford OX3 7FY, 
UK 
2School of Health, Sport and Bioscience, University of East London, Water Lane, London, 
E15 4LZ, UK 
 
 
 
 
 
 2
Abstract 
Animal models of arthritis are widely used to de-convolute disease pathways and to identify 
novel drug targets and therapeutic approaches. However, the high attrition rates of drugs in 
Phase II/III rates means that a relatively small number of drugs reach the market, despite 
showing efficacy in pre-clinical models. There is also increasing awareness of the ethical 
issues surrounding the use of animal models of disease and it is timely, therefore, to review 
the relevance and translatability of animal models of arthritis. In this paper we review the most 
commonly used animal models in terms of their pathological similarities to human rheumatoid 
arthritis as well as their response to drug therapy. In general, the ability of animal models to 
predict efficacy of biologics in man has been good. However, the predictive power of animal 
models for small molecules has been variable, probably because of differences in the levels 
of target knockdown achievable in vivo. 
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1. INTRODUCTION 
Animal models of arthritis have been used extensively to test identify drug targets for 
rheumatoid arthritis (RA) and test potential therapeutics. However, concerns about low clinical 
development success rates for investigational drugs (Hay et al., 2014), coupled with 
increasing awareness of the ethical issues surrounding the use of animal models, have led 
many to question their utility. It is timely, therefore, to review the most commonly used models 
in terms of their pathological relevance to human RA and in terms of their response to 
therapeutic intervention. 
2. OVERVIEW OF RA 
RA affects 0.5-1% of the population in the UK and has a lifetime risk of 4% for women and 2% 
for men. For many, RA is a painful and disabling disease associated with chronic 
inflammation. RA is one of the most common causes of disability in the western world with the 
age of onset typically between 25 and 50, although it can occur at any age. The principal 
pathological features of the disease include inflammatory erosive synovitis that ultimately 
leads to destruction of cartilage, bone and soft tissues, resulting in long-term deformity and 
loss of joint function. Although joints are the main target of the disease process in RA, 
patients may present with extra-articular features, including sub-cutaneous nodules, vasculitis 
and pulmonary fibrosis, especially in the more severe cases. 
Conventional treatment choices RA include corticosteroids and disease-modifying anti-
rheumatic drugs (DMARDs) and for patients who fail to respond adequately to these drugs 
the additional use of biopharmaceuticals, in particular TNF inhibitors, offers greater 
opportunities for disease management. However, despite the undoubted success of anti-
TNFα, only a quarter of patients treated with a combination of a TNFα inhibitor plus 
methotrexate achieve disease remission (defined as a DAS-28 score of less than 2.6). In 
addition, up to 50% of primary responders lose their response within 12 months of the start of 
therapy (Buch et al., 2007). Hence, there remains a need for more effective anti-arthritic 
medicines. 
The search for new drugs goes hand-in-hand with attempts to understand the 
aetiopathogenesis of RA and genetic factors are known to play an important role in 
determining susceptibility to the disease. Indeed, the association between RA susceptibility 
and specific HLA DRB1 alleles has been demonstrated in a number of populations around the 
world (Silman and Pearson, 2002). A concept emerged more than a quarter of a century ago 
suggesting that CD4+ T cells play an important role in the pathogenesis of the disease 
(Janossy et al., 1981), due to the presence of large numbers of T cells in the joints of RA 
patients and the association of MHC class II with RA, for which the only known function is to 
present peptide antigens to CD4+ T cells. 
This has developed further with the increased understanding that RA patients present with 
different synovial pathological features that may relate to different RA phenotypes (Pitzalis et 
 4
al., 2013a). The complexities of ‘antigen drift’ as the disease develops, and accompanying 
differences in emphasis between cell types, such as CD4+, Th17, and B-cells during this 
evolution is making RA a disease that has increasing potential for personalised medicine. The 
prediction of clinical efficacy from RA animal models should therefore be accompanied with a 
deep understanding of the mechanisms employed and how they relate to the human disease 
(Pitzalis et al., 2013b). 
3. MODELS COMMONLY USED FOR DRUG TESTING 
(a) Collagen-induced arthritis (CIA) 
Arthritis is induced in susceptible strains of rats and mice by immunisation with type II 
collagen in incomplete Freund’s adjuvant (IFA) or complete Freund’s adjuvant (CFA), 
respectively (Holmdahl et al., 1989; Trentham, 1982). Both T helper (Th) 1 and (Th17) 
responses are induced in CIA, but Th17 cells appear to play the dominant pathological role 
(Murphy et al., 2003). The histology of CIA resembles RA in terms of the infiltrating cells in 
synovial tissue and destruction of bone and cartilage. CIA susceptibility is linked to the I-A 
region of the H-2q and H-2r haplotypes in mice. Analysis of the I-A chains of alleles from 
susceptible and resistant strain (B10.Q) indicated that susceptibility is associated with a four-
amino-acid sequence in the I-Aβ chain (Nabozny et al., 1994). This sequence is located in a 
region associated with binding antigenic peptide, analogous to the genetic susceptibility 
observed in RA in humans conferred by the DRβ chain. The induction of arthritis in mice of a 
C57BL/6 (H-2b) background (Campbell et al., 2000; Inglis et al., 2007a) has facilitated the use 
of gene knockout mice and a more recent development of this has been the generation of the 
congenic C57Bl/6N.Q strain, that expresses the arthritis susceptible q haplotype of the MHC 
class II region (Backlund et al., 2013). Rat collagen arthritis is the next most common model 
used, and is likewise based on the rat equivalent to murine Class 1a, namely MHC Class II 
RT1 complex, with susceptibility being dominant. 
(b) Adjuvant-induced arthritis  
The adjuvant-induced arthritis (AA) model was established following the finding that certain 
strains of rats develop arthritis following administration of CFA (Pearson, 1956). It was initially 
thought that components of the mycobacteria cross-reacted with joint-specific self-antigens, 
such as heat shock proteins (van Eden et al., 1988). However, even non-antigenic adjuvants, 
such as muramyl dipeptide, incomplete Freund’s adjuvant and CP20961 can also induce 
arthritis and it was suggested that these adjuvants may enhance reactivity to self-antigens in 
the joint (Kohashi et al., 1982). The mechanisms underlying induction of AA are not fully 
understood but the fact that susceptibility is linked to certain MHC class alleles (Lorentzen 
and Klareskog, 1996; Vingsbo et al., 1995) and that antibodies to CD4 and MHC class II 
molecules can inhibit disease (Holmdahl et al., 1992; Larsson et al., 1985) confirms the 
importance of CD4+ T cells. The mechanisms underlying CFA and the mineral oil arthritides 
are different, with the sensitisation to mycobacterial antigens playing a large role in the 
former. A difference between adjuvant and collagen arthritis is that resistance is dominant in 
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adjuvant disease, and MHC playing a lesser role, though still significant. Non-MHC 
phenotypes contribute significantly, such as the Aia1, Aia2, and Aia3 regions (Joe et al., 
2002). A difference between AA and RA is that AA displays a fairly rapid remission while 
human RA is a chronic disease. In contrast, arthritis induced by the lipid, pristane (2,6,10,14-
tetramethylpentadecane), follows a more chronic relapsing disease course (Bedwell et al., 
1987). 
(c) Antigen-induced arthritis 
Antigen-induced arthritis is seen in mice, rats and rabbits following intra-articular injection of 
protein antigen (e.g. methylated bovine serum albumin) into the knee joints of animals that 
have previously immunised with the same antigen (Brackertz et al., 1977; Dumonde and 
Glynn, 1962).The cellular basis is very similar to CIA, but with more tightly defined  
sensitisation and challenge steps that can be exploited. It is CD4+ T-cell dependent.The 
histopathological appearance of antigen-induced arthritis bears similarities to RA, including 
synovial lining layer hyperplasia, perivascular infiltration with lymphocytes and plasma cells, 
lymphoid follicles, pannus and cartilage erosions. Indeed repeated injections of antigen can 
induce ectopic lymphoid structures (ELS) similar in appearance to those seen in RA patient 
subsets. The erosiveness is related to the ability of the antigen to bind cartilage. However, 
unlike RA, antigen-induced arthritis is a monoarticular disease that affects only the injected 
joints. Susceptibility to antigen-induced arthritis is not MHC class II restricted and this makes 
the model useful for studies involving transgenic and gene knock-out mice. 
(d) Bacterial cell wall-induced arthritis  
Injection of bacterial cell wall structures can induce arthritis in susceptible strains of rats which 
is clinically similar to human RA. A single intraperitoneal injection of cell walls may induce a 
cycle of exacerbation and remission of arthritis. The development of arthritis is thought to be 
due to accumulation of bacterial cell wall fragments in the joints and once disease is initiated, 
recurrence can be triggered by microbial superantigens that activate T cells with specific Vβ 
genes in an antigen-independent manner (Schwab et al., 1993). 
(e) Spontaneous models  
Arthritis occurs spontaneously in mice expressing a modified transgene encoding human 
TNFα which has been dysregulated by the replacement of the 3’ AU rich region with the 3’ 
untranslated region of the human β-globin gene (Keffer et al., 1991). Synovial cells of the joint 
are a major source of the transgenic TNFα expression. 
The K/BxN model arose from transgenic expression of a TCR specific for a peptide from 
bovine pancreatic ribonuclease. These mice spontaneously developed arthritis when bred on 
to the NOD background (Kouskoff et al., 1996). Further studies revealed that the development 
of arthritis in K/BxN mice was dependent on I-Ag7 MHC class II molecules and could be 
blocked by treatment non-depleting anti-CD4 mAb (Korganow et al., 1999; Kouskoff et al., 
1996; Mangialaio et al., 1999). Although this is highly suggestive that the disease is driven by 
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CD4+ T cells, it was also found that the development of arthritis required the presence of B 
lymphocytes (Korganow et al., 1999; Kouskoff et al., 1996). Furthermore, transient arthritis 
could be transferred by injecting naive mice with serum IgG from arthritic mice in a 
complement-dependent and FcR-dependent manner, indicating the pathological role played 
by autoantibodies in this model (Corr and Crain, 2002; Korganow et al., 1999; Solomon et al., 
2002). The molecular target of the autoantibodies was identified as glucose-6-phosphate 
isomerase (GPI), a ubiquitous cytoplasmic enzyme in the context of I-Ag7 MHC class II 
molecules (Matsumoto et al., 1999). 
Sakaguchi et al described a model of arthritis that occurred spontaneously in mice carrying a 
point mutation of the gene encoding ZAP-70, a key signal transduction molecule in T cells. It 
was proposed that altered T-cell receptor signalling as a result of aberrant ZAP-70 leads to a 
failure in thymic deletion and the emergence of autoimmune T cells  (Sakaguchi et al., 2003). 
4.  How do animal models compare pathologically to human RA? 
The pathology of RA is not confined to the joint and involves complex pathways and multiple 
tissues. It is therefore imperative that any animal model chosen for investigation mimics 
enough of the human condition to be translatable. With a wide variety of models available, a 
thorough comparison is required to establish which model is appropriate for the research in 
question. All models discussed here exhibit classical features of RA, namely joint swelling, 
synovitis, pannus formation, and bone erosion (Table 1). However, each model differs in 
speed of disease onset, chronicity, severity, resolution and histopathology. Models such as 
hTNF transgenic mice (Keffer et al., 1991) or K/BxN mice (Kouskoff et al., 1996) develop 
spontaneous arthritis, potentially providing insights into disease triggers. In contrast, CIA is 
induced by collagen immunisation and is useful for assessing drug efficacy in a controlled 
manner. CIA is also useful for investigating the role of specific genes through the use of 
knockout mice (reviewed (Vincent et al., 2012)). Zap70 mutant SKG mice may develop 
arthritis spontaneously dependent on environmental factors or may require induction via 
zymosan administration (Yoshitomi et al., 2005).  
The histopathology of the rodent models also differs between each other, as well as with 
human RA (Patel et al., 2010). Most, including CIA and K/BxN, exhibit a periostitis with 
accompanying bone shaft involvement, erosion and proliferation. This is especially so in rat 
adjuvant arthritis (Patel et al., 2010). There is a heavy neutrophil involvement in rodent 
models, more so than human RA. In CIA the patterns of erosion are similar with erosion 
progressing from the joint margins through the underlying bone and over the cartilage 
surface. In rat adjuvant arthritis subchondral bone is degraded by a heavy neutrophilic 
invasion, depleting cartilage of matrix, but only eroding cartilage in the chronic fibrotic phase. 
It can be termed a periarthritis. Pristane arthritis has added features of neutrophil aggregates, 
not seen in either CFA or CIA arthritis. The adjuvant disease results in profound ankylosis in 
the chronic phases. Antigen induced arthritis progresses in a fashion similar to RA, and 
repeated injections of antigen induce ectopic lymphoid aggregates as seen in RA subsets.  
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The disease course in RA is usually progressive and persistent but it is common to have 
periods of flare and remission. Spontaneous models that reflect this are often more chronic 
and with a delayed disease onset but with the exception of K/BxN serum transfer (Ditzel, 
2004) there is no remission of disease. The hTNF transgenic mouse in particular is extremely 
destructive and erosive (Keffer et al., 1991; Probert et al., 1996). This is in contrast to CIA, 
which is acute but remitting in late disease (around 10-14 days post onset) (Mauri et al., 
1996).  
RA is a systemic disease and as such, multiple tissues can be affected. Most commonly 
extra-articular manifestations of RA are found in the lungs (interstitial lung disease/fibrosis), 
heart (arrhythmias and endocarditis) and eyes (ocular inflammation and secondary Sjörgen’s 
syndrome) (reviewed in (Cojocaru et al., 2010; Prete et al., 2011)). This has led to further 
investigation of the major animal models used in arthritis research to examine whether they 
also display some or all of this additional pathologies. Following immunisation with type II 
collagen, DBA/1 mice exhibited signs of pulmonary inflammation characterized by cellular 
infiltration and cytokine production but it did not correlate with arthritis score. This was largely 
due to CFA, as immunising with CFA alone without collagen was sufficient to induce lung 
inflammation. Under the same conditions there was no evidence for any cardiac pathologies 
or complications (Schurgers et al., 2012). The hTNF model has high systemic inflammation 
due to over expression of TNF with some evidence that there is lung and cardiac 
inflammation but this seems to be after targeting these tissues directly rather than an effect of 
the arthritis model (Franco et al., 1999; Fujita et al., 2001; Tang et al., 2004). Little is known 
about extra-articular manifestations in the K/BxN model, however there are reports of 
spontaneous endocarditis alongside arthritis in these mice, interestingly via different pathways 
(Binstadt et al., 2009).  There is also evidence of interstitial lung disease in the zymosan-
induced SKG model. Arthritic mice also develop pulmonary fibrosis that is similar to the 
interstitial lung disease found in some RA patients (Keith et al., 2012). There is limited 
understanding of whether these additional manifestations are responsive to anti-arthritic 
treatments and there is scope to further investigate multiple tissue pathology in these models. 
Rat CFA arthritis is also a systemic disease, with connective tissue inflammation involving 
eyes, meninges, skin, bone marrow, increased gut permeability, splenomegaly, and 
granulomatous liver disease (Patel et al., 2010).   
Chronic pain is a prominent feature of RA and pain relief is an unmet need in many patients. 
Animal models of arthritis have been used to assess pain and analgesics. In CIA, disease 
onset results in a decrease in threshold to mechanical and thermal stimuli when testing 
evoked pain response, making it a suitable model to test analgesics. Indeed, treating with 
anti-TNF from onset in CIA is analgesic as well an anti-arthritic, leading to normalisation of 
pain and spontaneous behaviour responses (Inglis et al., 2007b).  Using the K/BxN serum 
transfer model to assess joint pain in mice, a reduction in thermal and mechanical threshold 
was displayed that correlated with joint swelling. Thermal latency returned to control levels 
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with resolution of disease but mechanical sensitivity persisted beyond the inflammatory phase 
(Christianson et al., 2012). These models therefore provide a valuable opportunity to 
investigate persistent sensitisation in arthritis as even with successful therapy, many patients 
continue to require pain relief. CFA arthritis, or simply CFA injection into the paw, is used in 
RA pain research, with spinal indices of hyperalgesia being demonstrated, thermal and 
mechanical thresholds also being reduced.    
5. Immune system involvement in RA and animal models: how do they compare? 
The aetiology of RA is remains elusive, but it is accepted that genetic susceptibility and 
environmental triggers are important in causing altered immune function, resulting in 
autoimmunity. 
The presence of autoantibodies is a predominant feature of RA. Rheumatoid factor (RF) is 
found in 70-90% of RA patients but is also detected in healthy individuals and patients with 
other autoimmune disorders (Dorner et al., 2004; Dorner and Hansen, 2004). The presence of 
anti-citrullinated protein antibodies (ACPA) is also highly specific to RA (over 90%) and linked 
with a more progressive, destructive arthritis (Klareskog et al., 2008; Silveira et al., 2007; Snir 
et al., 2010). ACPA have been described up to 10 years before disease onset and are 
additionally correlated with RA risk factors such as smoking and periodontal disease 
(Hensvold et al., 2015; Mahdi et al., 2009; Wegner et al., 2010). RF is generally thought to be 
absent from rodent models, but aggressive erosive disease is linked to the presence of anti-
citrullinated cyclic peptide antibodies (anti-CCP) which may be generated within RA pannus 
ELS. CIA mice have been found to develop measurable levels of antibodies specific for 
certain citrullinated epitopes (Vossenaar et al., 2003). Indeed peptidyl arginine deiminase 
(PAD) that generates citrullinated peptides, is expressed in CIA synovia, and citrullination of 
CII enhances the arthritogenic activity (Lundberg et al., 2005).  Both ACPA and RF have been 
described in the CIA model in C57BL/6Q mice (Forster et al., 2012) and in SKG mice (Hsu et 
al., 2009) (Keith et al., 2013) but there are no reports of ACPA in KxB/N or hTNF mice.  
The major histocompatibility complex (MHC) is a gene family separated into 3 classes. Class 
II molecules are found on APCs and govern presentation of antigens to CD4+ T cells. RA 
susceptibility is associated with specific alleles within MHC class II, namely HLA DRB1 
(Newton et al., 2004a; Newton et al., 2004b). The frequency of HLA DRB1 alleles is increased 
in patients with RA when compared to healthy controls (McInnes and Schett, 2007). These 
alleles have a common sequence termed the shared epitope, and around 90% of RA patients 
are positive for this sequence (Gregersen et al., 1987). As in human RA, MHC class II 
molecules are known to determine disease susceptibility in many animal models of arthritis. 
The SKG model is MHC class II linked (Sakaguchi et al., 2003), and CIA is normally carried 
out in mice bred onto specific MHC susceptible haplotype backgrounds (I-Aq is the most 
common) (Williams, 2007). CIA rats share some susceptibility haplotypes with human arthritic 
haplotypes (Watson et al., 1990). The MHC phenotype is not as strong in CFA and adjuvant 
arthritis, in pristane arthritis susceptibility results from negative associations such as Rt1n and 
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Rt1h. However, heterogenous nuclear ribonucleoprotein A2 (hnRNP-A2) has been identified 
from epitope screening of RA associated auto-antigens, which indicates a reliance on MHC. 
In CFA, MHC quantitative trait loci such as Aia2, and Aia3 on chromosome 4 are important. 
Aia1, 2 and 3 contain autoimmunity candidate genes, for example Aia3 : RA2.  
KRN mice on an I-Ak background do not develop arthritis, but when crossed with animals 
expressing I-Ag7 molecules, develop disease (Ditzel, 2004). Although MHC class II genes are 
important, non-MHC genes are also suggested to be required (Kobezda et al., 2014). 
MHC class II molecules present antigens to CD4+ T cells and these cells are present in the 
synovium of inflamed joints in both humans and animals (Alzabin and Williams, 2011; Todd et 
al., 1988). The requirement for CD4+ T cells in the initiation of arthritis has been 
demonstrated in CIA by anti-CD4 mAb treatment prior to onset, however it does not 
ameliorate established disease (Williams and Whyte, 1996), a result reflected in human 
clinical trials (Keystone, 2002). This failure to ameliorate established disease is likely to be 
due to the depletion of all CD4 subsets, including regulatory T cells. As depletion of CD4+ T 
cells fails to halt joint destruction, the focus has shifted to specific CD4+ T cell populations. 
Th1 and Th17 cells are defined by their expression of IFN-γ and IL-17, respectively. IFN-γ 
and IL-17 are found to be elevated in the circulation and inflamed joints of RA patients and 
many animal models of arthritis and targeting IL-17 has proved therapeutic in CIA (Lubberts 
et al., 2004) (Nakae et al., 2003), K/BxN mice (Jacobs et al., 2009) and particularly SKG mice 
in which disease is strongly driven by Th17 cells (Hirota et al., 2007) although the results of 
IL-17 blockade in human RA have been relatively disappointing (Genovese et al., 2013). Th17 
and Th1 cells paradoxically increase in RA patients following anti-TNF therapy, an 
observation first seen in the CIA model (Notley et al., 2008). Blockade of TNF results in an 
increase in the IL-12/IL-23 subunit p40 (IL-12 and IL-23 are important for Th1 and Th17 
survival, respectively) and further studies have linked increased Th17 and Th1 cells with non-
response to anti-TNF in RA patients (Alzabin et al., 2012; Chen et al., 2011). 
Regulatory T (CD4+CD25+FOXP3+) cells are known to be defective in RA (Ehrenstein et al., 
2004) with a reduced capability to suppress inflammatory cytokine production and increased 
apoptosis (Toubi et al., 2005). Many models of arthritis have shown that these cells are 
disease modifying. Thus, depletion of Tregs exacerbates disease and adoptively transferring 
Tregs into CIA is therapeutic (Morgan et al., 2005). Arthritis in K/BxN mice without functional 
foxp3 is more destructive (Nguyen et al., 2007). Anti-TNF restores Treg suppressor function 
and prevents apoptosis of these cells but there is conflicting evidence with some studies 
demonstrating an additional protective role for TNF. In support of this, FoxP3 intensity 
increased following longer TNF exposure in co-cultures of Tregs and T effector cells. This 
resulted in enhanced suppressive activity and reduction of cytokines via TNFRII (Chen et al., 
2007). These conflicting reports and the suggested involvement of TNFRII have led to a focus 
on the TNF receptors and Tregs in animal models of arthritis. A recent study in CIA 
highlighted a divergent role for TNF receptors in Tregs. Thus, selective blockade of TNFR1 
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resulted in expansion of Treg cells and increased suppressive function (including significant 
reductions in IL-17 and IFN-γ) not seen when targeting both receptors using TNFR-Fc 
(McCann et al., 2014). It was also suggested that by preserving TNFRII, the resolution of 
disease is enhanced, associated with increased foxp3 expression in the joints. Whether a 
there is a role for TNFRII in human Tregs remains to be established but certainly merits 
further investigation. 
6. Comparison of drug therapy in RA and animal models 
(a) Biologics 
Anti-TNF has been enormously effective in RA and has transformed the therapeutic 
landscape. It was the discovery that synovial explants from RA patients spontaneously 
produced TNF-α and that blockade of TNF in culture demonstrated that production of other 
pro-inflammatory proteins implicated in RA (IL-1β and GM-CSF) was dependent on TNF, 
making it a pivotal mediator of disease (Brennan et al., 1989; Haworth et al., 1991). Using the 
CIA model of arthritis, neutralising TNF was found to ameliorate inflammation and impede 
joint destruction (Williams et al., 1992). In addition, administration of anti-TNF antibodies to 
hTNF transgenic mice reduced TNF-induced mortality (Siegel et al., 1995). The clear efficacy 
of anti-TNF in the models translated into the clinic, with around 70% of patients reporting a 
20% or more reduction in symptoms (Maini et al., 1998). 
A proportion of patients respond poorly to anti-TNF and focus has now returned to the models 
to reassess anti-TNF therapy and identify novel biologic targets that could be tested in 
patients. As discussed previously here, IL-17 was established as a potential target through 
the CIA and SKG models but lacked efficacy in human RA (Genovese et al., 2013). Ant-IL-17 
mAb therapy continues to be explored as a therapy for RA, particularly for anti-TNF non-
responders and in other related autoimmune disorders such as psoriasis and anklosing 
spondylitis. IL-6 is known to promote Th17 differentiation (Bettelli et al., 2006; Korn et al., 
2009) and elevated levels of IL-6 have been found in the synovial fluid of RA patients (Hirano 
et al., 1988; Houssiau et al., 1988; Robak et al., 1998). The joints of SKG mice have 
enhanced IL-6 gene expression and protein when compared to BALB/c mice and IL-6-/- SKG 
mice are protected from synovitis and joint destruction and fail to produce Th17 cells (Hirota 
et al., 2007). Blockade of IL-6 is also efficacious when administered early in CIA (Fujimoto et 
al., 2008) and anti-IL-6 therapy (tocilizumab) has been successful in multiple trials and is 
approved for clinic use for RA patients reviewed in (Navarro-Millan et al., 2012). 
In addition to blockade of pro-inflammatory cytokines, there are also biologics that target T 
cell activation, most notably abatacept. Abatacept disrupts the interaction between CD28 
(expressed on T cells) and CD80 and CD86 (expressed on APCs) using a enhanced binding 
homolog of CD28, CTLA-4. Abatacept is made from the extracellular portion of CTLA-4 fused 
to human IgG1 Fc (CTLA-4Ig) (Bevaart et al., 2010). When given to rats or mice 
prophylactically, CTLA-4Ig supresses disease onset in CIA and reduces proliferating T cells in 
the lymph nodes draining the site of immunisation (Knoerzer et al., 1995; Webb et al., 1996). 
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CTLA-4Ig was also found to be efficacious in ameliorating clinical score when the treatment 
was given after disease onset (Knoerzer et al., 1995). In RA patients, abatacept is therapeutic 
in a number of trial conditions including anti-TNF non-responders (Schiff, 2011). 
Another validated approach in human RA is anti-B cell (anti-CD20) mAb therapy, which is 
administered primarily to anti-TNF non-responders (Tak et al., 2012). Although anti-CD20 
treatment has not been tested specifically in animal models, B cell deletion or depletion is 
known to protect against arthritis (Svensson et al., 1998; Yanaba et al., 2007) and anti-CD19 
mAb therapy was found to effective in CIA, without depleting B cells (Cemerski et al., 2010). 
Animal models of arthritis have undoubtedly facilitated the positive progress of biologics from 
the lab to the clinic and in general, concordance has been observed between animal models 
and human disease. 
(b) Small molecules 
Despite the success of biologics to treat RA, they remain expensive to produce and may only 
be administered intravenously or subcutaneously (Liu et al., 2012). To address this, small 
molecular inhibitors (SMIs) have been investigated due to their lower manufacturing costs and 
oral availability (Stanczyk et al., 2008). SMIs are compounds with a molecular weight less 
than 1kDa and those targeting inflammation are largely kinase inhibitors. The rationale for 
kinase inhibition is that they often act upstream of inflammatory mediators including TNF. 
Mitogen-activated protein kinases (MAPKs) are a well-described pathway involved in 
inflammation. They comprise three groups; p38, c-Jun N-terminal kinase (JNK) and 
extracellular-regulated protein kinase (ERK) with p38 the most explored for treatment 
potential. Inhibition of various p38 inhibitors proved therapeutic in CIA and other models of 
arthritis, but numerous p38 inhibitors did not progress past phase III RA trials with both 
toxicity and poor efficacy cited for their failure in the clinic (Hammaker and Firestein, 2010). 
Tyrosine kinases (JAK and Syk) were the next front runners to emerge from animal models 
(largely rat and mouse CIA) but with mixed success in the clinic. The JAK family antagonist 
tofacitinib compared favourably against methotrexate and anti-TNF but due to concerns over 
the safety profile, it is currently not approved for RA treatment in Europe but is FDA-approved 
in the US (Cutolo and Meroni, 2013; Garber, 2011). Fostmatinib inhibits Syk kinases 
important for immune cell signalling as well as osteoclastogensis. After phase III trials in RA, 
fostmatinib failed to match the efficacy of anti-TNF and is not currently expected to progress 
further (Fleischmann, 2015).  
Animal models as then used have shown to be poor predictors of efficacy for some kinase 
inhibitors but other SMIs are proving more fruitful, particularly some type 4 
phosphodiesterases (PDE4) inhibitors.  PDE4 hydrolyses cAMP to AMP and is expressed in 
immune cells (Page and Spina, 2011). Targeting PDE4 has been shown to reduce TNF in 
vitro via the protein kinase pathway (PKA) due to the elevation in cAMP (Seldon et al., 1995). 
Although their anti-inflammatory potential is promising, toxicity issues have stopped some 
PDE4 inhibitors from reaching the clinic (Palfreeman et al., 2013). Apremilast is a novel PDE4 
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inhibitor that has been investigated for its tolerability and efficacy in mouse CIA and collagen 
antibody induced arthritis (CAIA) and significantly reduced clinical score and joint pathology in 
both. Naïve mice showed no adverse behavioural changes when treated with apremilast in 
contrast to another PDE4 inhibitor, rolipram, where mice exhibited significant lethargy 
(McCann et al., 2010). Apremilast has shown efficacy in RA as a monotherapy with only mild 
adverse events and has been FDA approved for psoriatic arthritis.  
Although all animal models of disease will have limitations, their similarities and dissimilarities 
have furthered our understanding of RA and facilitated transfer of a number of successful 
therapies to the clinic. Despite this, the high attrition rate of small molecules in Phase III 
clinical trials (often due to adverse effects not predicted from animal toxicology) gives cause 
for concern and suggests that pre-clinical studies, particularly with small molecules, should be 
interpreted with more caution.  
Drugs are administered in animal models at doses that take no consideration of long term 
toxicity. However, dosing and target therapeutic levels in clinical trial necessarily take a more 
cautious approach. The failure of the early p38 trials appears to relate to the degree of kinase 
inhibition achieved in the clinic, as opposed to the animal models. The latest generation are 
focussing on upstream kinases, or dual-site p38 inhibitors designed for enhanced inhibitory 
activity (Wrobleski et al., 2013). BMS-582949, an example of the latter, does not suffer from 
the clinical tachypylaxis of the first generation, but did from side effects that could not be 
modelled in animals (Liu et al., 2013). Dual Inhibition of p38 kinase activation and activity 
provides efficacy in treatment of rheumatoid arthritis. (Schieven, 2012). The use of biologics 
(developed using animal models) has raised the benchmark for clinical efficacy and now it is 
seen that drugs which would have been ground breaking one to two decades ago, are now 
considered not to reach the efficacy required.  
This clinical judgment can now be made following the introduction of clinical assessment tools 
such as the ACR and EULAR response criteria, enabling the comparison between clinical 
trials. Animal modelling has not attained this level of sophistication, and in isolation is 
currently unable to make that level of prediction. Where animal modelling contributes, is when 
the degree of target knockdown is related to efficacy and drug exposure. Taking into account 
toxicity, this can be translated to the clinic, calibrating and adapting doses against biomarkers 
of efficacy against the target. 
7. THE 3R’s 
Animal models of arthritis will continue to be used in drug development and it is important that 
implementation of the 3R’s; replacement, reduction and refinement, is encouraged within 
research establishments and companies and by regulators, funding bodies and journals. A 
Joint Working Group held recently in London on the application of the three R’s to animal 
models of arthritis identified the following priority areas.  
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 Further research into the use of analgesia, with respect to suitable agents, effects on 
welfare and the science, timing of administration and self-administration.  
 Improved indicators of pain and distress, such as accessible computer-assisted 
behavioural analysis. 
 Less severe models, e.g. not requiring the use of potentially severe inducers such as 
CFA. 
 More physiologically relevant spontaneous models using GA mice, which will 
decrease the number of procedures because it will not be necessary to induce RA.  
 International guidelines for refined experimental protocols, including humane 
endpoints. 
 Better sharing and publication of all Three Rs in RA studies. 
 Greater support for the development and uptake of in vitro, in silico and 
epidemiological approaches to RA research. 
8. Conclusions 
Animal models of arthritis continue to play an important role in pre-clinical research, 
particularly for the identification and validation of drug targets. However, their predictive power 
for the levels of efficacy now required in the clinic is variable. They also  appear unable to 
predict long term adverse effects (e.g. infection risk). which often emerge in large-scale 
Phase III clinical trials. The use of models requires more considered approaches to 
integration into the drug development process, especially with respect to calibrating the 
degree of target knockdown to efficacy and then safety. The application of the Three R’s, 
particularly towards the refinement of existing models of arthritis, remains an important priority 
for the future. 
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Feature in human RA CIA hTNF transgenic  K/BxN  Spontaneous/zymosan induced arthritis in SKG  
Joint pathology 
           
Swelling of multiple joints Yes polyarthritis occurs 21-28 days post immunisation Yes from 4 weeks old 
Yes from 4 weeks old in 
transgenic strain or 7-14 
days after serum transfer 
into naïve mice 
Yes by 2 weeks post zymosan 
injection or 2 months in 
spontaneous model 
Synovitis Yes synovitis is evident by 10 days post disease onset Yes from 4 weeks old Yes Yes 
Pannus formation Yes pannus is observed by 7-10 days post disease onset Yes by 10 weeks old Yes Yes 
Cartilage degradation Yes observed by 7-10 days post disease onset Yes by 10 weeks old Yes Yes 
Bone erosion Yes  observed by 10 days post disease onset Yes by 10 weeks old Yes Yes 
Chronic pain 
Yes from disease onset, 
reduced with effective anti-
arthritic therapy 
Not investigated in this model 
but likely due to the 
established role of TNF in 
promoting inflammatory pain 
Yes in serum transfer model 
from disease onset and 
persists post inflammation 
resolution 
Not investigated but likely due to 
persistent swelling and redness 
in the joints 
     
      
Extra-articular patholology         
Pulmonary Fibrosis 
Partial lung involvement 
(variable and due to CFA) not 
correlated with clinical score 
Some lung involvement but 
overexpression of TNF is 
not enough to produce 
None reported 
 Lung disease resembling 
fibrosis 12 weeks post 
zymosan i.p injection 
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fibrosis without additional 
insult 
Cardiac involvement None reported or negative 
Yes cardiomyopathy and 
arrhythmias in cardiac-
specific TNF 
overexpression 
Yes cardiac valve 
inflammation None reported  
Ocular inflammation None reported None reported None reported None reported  
  
        
Auto-antibodies         
Citrillinated proteins (ACPA) Yes (reported in C57BL/6Q mice) No No 
Yes due to altered thymic 
selection 
Rheumatoid Factor Yes (reported in C57BL/6Q mice) No No 
Yes due to altered thymic 
selection 
 
